Close Menu

epigenetics

The company is planning to commercialize its cancer early detection technology initially in lung cancer and is working with NYU researchers to explore future expansions.

DARPA program managers said they are developing different testing modalities that are crucially linked in their objective to facilitate more comprehensive and faster testing.

The company had been working to expand its retrospective data over the last year and half and is now readying to move forward with prospective studies.

The company intends to develop its fragmentomic approach for early cancer detection both in individual tumor types and for multi-cancer screening.

Backed by large public companies and growing prospective data, the first molecular blood tests to screen for multiple cancers are approaching commercialization.

The companies said Tuesday that they are pursuing a clinical trial utilizing their respective liquid biopsy assays on clinical samples from lung cancer patients.

Shares of Illumina fell in afternoon trading on the Nasdaq following a brief rise after the market open.

The company recently had a second pre-submission with FDA and expects to begin a prospective trial of its test in the second half of this year.

The Oslo-based company plans to develop a test that can identify high-risk individuals based on an epigenetic signature.

The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.

Pages